SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Muhammad Khan, Jing Ouyang, Karen Perkins, Sunil Nair, Franklin Joseph, Determining Predictors of Early Response to Exenatide in Patients with Type 2 Diabetes Mellitus, Journal of Diabetes Research, 2015, 2015, 1

    CrossRef

  2. 2
    Yukiko Onishi, Elisabeth Niemoeller, Yukio Ikeda, Hiroki Takagi, Daisuke Yabe, Yutaka Seino, Efficacy and safety of lixisenatide in Japanese patients with type 2 diabetes mellitus inadequately controlled by sulfonylurea with or without metformin: Subanalysis of GetGoal-S, Journal of Diabetes Investigation, 2015, 6, 1
  3. 3
    Kenjiro Imai, Tetsuro Tsujimoto, Atsushi Goto, Maki Goto, Miyako Kishimoto, Ritsuko Yamamoto-Honda, Hiroshi Noto, Hiroshi Kajio, Mitsuhiko Noda, Prediction of response to GLP-1 receptor agonist therapy in Japanese patients with type 2 diabetes, Diabetology & Metabolic Syndrome, 2014, 6, 1, 110

    CrossRef

  4. 4
    Masao Toyoda, Hiroki Yokoyama, Katsushige Abe, Shuji Nakamura, Daisuke Suzuki, Predictors of response to liraglutide in Japanese type 2 diabetes, Diabetes Research and Clinical Practice, 2014, 106, 3, 451

    CrossRef

  5. 5
    Yoshinobu Kondo, Shinobu Satoh, Joe Nagakura, Masayo Kimura, Uru Nezu, Yasuo Terauchi, Defining criteria for the introduction of liraglutide using the glucagon stimulation test in patients with type 2 diabetes, Journal of Diabetes Investigation, 2013, 4, 6
  6. 6
    Junji Kozawa, Tetsuhiro Kitamura, Hitoshi Nishizawa, Tetsuyuki Yasuda, Norikazu Maeda, Michio Otsuki, Kohei Okita, Hiromi Iwahashi, Hideaki Kaneto, Tohru Funahashi, Akihisa Imagawa, Iichiro Shimomura, Dipeptidyl peptidase-4 inhibitors are effective in Japanese type 2 diabetic patients with sustained endogenous insulin-secreting capacity, a higher body mass index and insulin resistance, Journal of Diabetes Investigation, 2013, 4, 2
  7. 7
    Daisuke Fujiwara, Kenji Takahashi, Takahiro Suzuki, Masakazu Shii, Yukako Nakashima, Sato Takekawa, Atsushi Yoshida, Takashi Matsuoka, Postprandial serum C-peptide value is the optimal index to identify patients with non-obese type 2 diabetes who require multiple daily insulin injection: Analysis of C-peptide values before and after short-term intensive insulin therapy, Journal of Diabetes Investigation, 2013, 4, 6
  8. 8
    Katsumi Iizuka, Reiko Tomita, Yukio Horikawa, Jun Takeda, Effectiveness of the glucagon test in estimating islet function for liraglutide treatment in a lean diabetic patient with impaired insulin response to glucose, Diabetology International, 2012, 3, 2, 103

    CrossRef